drugset / Trial / NCT00003679

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00003679

Phase 3 Unknown 350 enrolled Scottish Cancer Therapy Network
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether doxorubicin plus docetaxel is more effective than doxorubicin plus cyclophosphamide for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of doxorubicin in combination with either docetaxel or cyclophosphamide in treating women who have previously untreated, advanced, or inflammatory breast cancer.

Timeline

Start
1998-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Docetaxel Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Background Tamoxifen Small molecule Oral

Indications